Detalles de la búsqueda
1.
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant Variants.
J Infect Dis;
228(8): 1055-1059, 2023 10 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-37280116
2.
Molecular Characterization of AZD7442 (Tixagevimab-Cilgavimab) Neutralization of SARS-CoV-2 Omicron Subvariants.
Microbiol Spectr;
: e0033323, 2023 Mar 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36877050
3.
Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial).
Infect Dis Ther;
12(12): 2691-2707, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37914983
4.
Longitudinal analyses using 18F-Fluorodeoxyglucose positron emission tomography with computed tomography as a measure of COVID-19 severity in the aged, young, and humanized ACE2 SARS-CoV-2 hamster models.
Antiviral Res;
214: 105605, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37068595
Resultados
1 -
4
de 4
1
Próxima >
>>